CLINICAL_TRIALS
trial_result
· 2024-06-03
Clinical Trial Update: Baricitinib for the Lung Injury Following Spontaneous SAH [Phase 2]
Summary
A Phase 2 trial of baricitinib for lung injury following spontaneous subarachnoid hemorrhage is listed, with the study currently not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tang-Du Hospital | Conditions: Spontaneous Subarachnoid Hemorrhage | Phase 2 | Status: NOT_YET_RECRUITING